Table 3.
Performance of HOMA-IR values in the classification of cardio metabolic risk (both ATPIII MetS and IDF MetS definition), influence of age and gender
| ROC coefficients* | P value | AUC (95% CI) | ||
|---|---|---|---|---|
| A |
Males |
|
|
|
| IDF MetS |
|
|
|
|
| • Age |
0.0102 |
0.1665 |
0.69 (0.65, 0.74) |
|
| • Intercept |
−1.1411 |
0.0048 |
|
|
| ATPIII Mets |
|
|
|
|
| • Age |
0.0117 |
0.1897 |
0.72 (0.67, 0.77) |
|
| • Intercept |
−1.2976 |
0.0089 |
|
|
| |
Females ** |
|
|
|
| |
IDF MetS |
|
|
|
| • Age 30 yr |
|
|
0.82 (0.71, 0.90) |
|
| • Age 50 yr |
|
<0.001 |
0.77 (0.68, 0.82) |
|
| • Age 70 yr |
|
|
0.58 (0.48, 0.68) |
|
| |
ATPIII MetS |
|
|
|
| • Age 30 yr |
|
|
0.83 (0.71, 0.91) |
|
| • Age 50 yr |
|
0.012 |
0.80 (0.71, 0.85) |
|
| • Age 70 yr |
|
|
0.61 (0.52, 0.70) |
|
| B |
Males |
|
|
|
| IDF MetS |
|
|
|
|
| • Age |
−0.0113 |
0.8998 |
0.68 (0.59, 0.78) |
|
| • Intercept |
0.1406 |
0.5160 |
|
|
| ATPIII MetS |
|
|
|
|
| • Age |
−0.0029 |
0.8595 |
0.72 (0.62, 0.81) |
|
| • Intercept |
−0.4692 |
0.6515 |
|
|
| |
Females |
|
|
|
| |
IDF MetS |
|
|
|
| • Age |
−0.0010 |
0.9656 |
0.54 (0.44, 0.64) |
|
| • Intercept |
0.0173 |
0.9914 |
|
|
| |
ATPIII MetS |
|
|
|
| • Age |
−0.0010 |
0.9656 |
0.54 (0.44, 0.64) |
|
| • Intercept | 0.0173 | 0.9914 |
Areas under the ROC curves for non-diabetic (A) and diabetic (B) adults (n = 2459).
AUC (95% CI), area under the ROC curve (95% Confidence Interval). *ROC regression models incorporating age as covariate. **The AUC was estimated for three ages (30, 50, and 70 years) to illustrate the performance of HOMA-IR. HOMA-IR, homeostasis model assessment of IR; ATPIII, Third Adult Treatment Panel; IDF, International Diabetes Federation; MetS, Metabolic Syndrome.